Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab +/- Nivolumab for Glioblastoma and Melanoma Brain Metastases
NCT05909618Phase 2Recruiting
- Sponsor
- Sheba Medical Center
- Start
- Jul 2023
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of crizanlizumab in glioblastoma (GBM) and melanoma (3 arms), sponsored by Sheba Medical Center. Primary endpoints: Incidence of treatment-related adverse events and serious adverse events at 48 months and Proportion of treatment discontinuation events at 48 months. Started Jul 2023; status: recruiting.
02
Drugs
crizanlizumab
03
Conditions
glioblastoma (GBM)melanoma
Beyond the preview
Go deeper on NCT05909618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909618.